Stereotactic body radiation therapy (stereotactic ablative radiotherapy) for stage I non-small cell lung cancer--updates of radiobiology, techniques, and clinical outcomes.
Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy (SABR), has emerged as one of the standard treatment options for stage I non-small cell lung cancer (NSCLC), mainly in medically inoperable patients. Its use has also been explored in operable patients. A large body of experience, either from retrospective studies or clinical trials, has been accumulated over the years and more is known about the radiobiology, cancer biology, technical aspects, clinical outcomes, and toxicities of SBRT. This article provides updates of these aspects of SBRT for stage I NSCLC.
Hadziahmetovic
Mersiha
M
Department of Radiation Oncology, Arthur G. James Cancer Hospital, Ohio State University, Columbus, OH 43210, USA.
Loo
Billy W
BW
Timmerman
Robert D
RD
Mayr
Nina A
NA
Wang
Jian Z
JZ
Huang
Zhibin
Z
Grecula
John C
JC
Lo
Simon S
SS
D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology* / Q000601:surgery*; D002986:Clinical Trials as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000601:surgery*; D011853:Radiobiology / Q000379:methods*; D016634:Radiosurgery / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome